Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month

Proclamation heightens public awareness and impact of the devastating infection


Download this press release (328 KB).

ROSEVILLE, MN an – November 01, 2018 — Rebiotix Inc, a late-stage biotechnology focused on harnessing the power of the microbiome to treat debilitating diseases, joined the C. Diff Foundation today to congratulate the State of Minnesota for declaring November “Clostridium difficile Awareness Month.” Rebiotix, part of the Ferring Pharmaceuticals Group, and the C. Diff Foundation indicated that the proclamation approved by the office of Governor Mark Dayton serves to heighten awareness of the impact this disease has on patients in Minnesota and across the United States. The infection, which has been labelled an urgent national health threat by the Centers for Disease Control (CDC), results in 500,000 infections each year and is directly responsible for more than 29,000 deaths annually.

Clostridium difficile infection is recognized as the number one healthcare associated infection in the U.S,” says Lee Jones, president and CEO of Rebiotix. “It’s a debilitating, isolating, and potentially life-threatening condition. We applaud both the C. Diff Foundation and Governor Dayton’s administration for bringing awareness to this significant health concern, and look forward to continuing to develop novel therapies to address this unmet need.”

Rebiotix’s first product, RBX2660, is currently in a Phase 3 clinical trial for the prevention of recurrent Clostridium difficile infection. It is the most clinically advanced product of the company’s Microbiota Restoration Therapy™ drug platform. The second product, known as RBX7455, a lyophilized, non-frozen, room-temperature stable oral formulation, was recently studied in a Phase 1 investigator-sponsored trial for recurrent Clostridium difficile infection.

“Supporting C. diff patients, their families, and the providers who care for them requires leadership across all fields – from governmental institutions, to advocacy, to academia and industry,” says Nancy Caralla, founder of the C. Diff Foundation. “On behalf of C. diff patients, we applaud the efforts of the State of Minnesota and Rebiotix for playing such an important role in raising awareness about CDI. This is a critical part to reducing the impact and rate of the infection everywhere.”


About Rebiotix Inc.

Rebiotix Inc, part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix’s lead drug candidate, RBX2660, is in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection and has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized non-frozen, room-temperature stable oral capsule formulation, which was recently the subject of an investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff infection. In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ platform. The MRT platform is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. Learn more at www.ferring.com.

About the C Diff Foundation

The C Diff Foundation is a non-profit, 501(c)(3) organization established in 2012. It is comprised of 100% volunteering professionals dedicated to supporting public health through education and advocacy for C. difficile infection prevention, treatments, environmental safety and support world-wide. The Foundation’s CEO and founder is a nurse inspired to create the foundation after witnessing the loss of her father to CDI, as well as suffering from the infection herself. The C Diff Foundation members, with their volunteer patient advocates, successfully “raise C. diff awareness” locally and in over fifty-six (56) countries and host a U.S. nation-wide hotline (1-844-FOR-CDIF) to support healthcare providers, patients and families through the difficulties of a C. diff infection.

Rebiotix Media Contact:
Courtney Jones
651-705-8774
cjones@nullrebiotix.com

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.